Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Ch...( Technology Turns Off 'Master Switch' ...),Health

Technology Turns Off 'Master Switch' Underlying Bacterial Infection and May

Have Broad Use in Preventing Critical Bacterial Infections

BOSTON, Sept. 18 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. announced today the most advanced preclinical results of the Company's Multiple Adaptation Response (MAR) inhibitor program. MAR proteins in bacteria serve as the "master switch" controlling virulence and antibiotic resistance. Paratek has shown that shutting down this switch disables bacterial virulence and prevents bacteria from causing infection. Paratek is developing MAR inhibitors that can prevent serious and life-threatening bacterial infections in high-risk patients.

The results were reported in a "late breaker" poster presentation titled, "A Novel Anti-Virulence Approach for Treatment of Pneumonia Caused by Pseudomonas aeruginosa," at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Chicago. The findings demonstrated that small molecule agents which block the activity of ExsA (a MAR protein) in Pseudomonas aeruginosa significantly reduced bacterial virulence and were protective in an animal model from pneumonia. Lead authors on the research are Michael P. Draper, Ph.D., Director of Anti-Infective Drug Discovery at Paratek Pharmaceuticals, and Stuart B. Levy, M.D., Chief Scientific Officer and Co-Founder of Paratek.

In addition, Paratek announced a newly released publication showing efficacy of the Company's MAR inhibitors against E. coli in urinary tract infection in another animal model of serious bacterial infection. The article, titled, "Novel anti-infection agents: Small-molecule inhibitors of bacterial transcription factors," is appearing in the current August 2007 issue of Bioorganic & Medicinal Chemistry Letters.

Dr. Levy commented, "We are very pleased with the progress of the MAR program. We have shown proof of concept in E. coli, Yersinia and now Pseudomonas, a gram-n
'/>"/>